相关实验视频

Updated: Jun 21, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

第一线奥西默提尼布治疗不常见的EGFR外19突变和EGFR复合突变的肺癌

Tia Cheunkarndee1, Matthew Z Guo1, Stefanie Houseknecht1

  • 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

JTO clinical and research reports
|July 8, 2024
PubMed
概括

奥西默提尼布在患有不常见EGFR突变的非小细胞肺癌 (NSCLC) 患者中显示出有前途的疗效,包括非典型的EXON 19和复合突变. 需要进一步的研究,以优化这些罕见病例的治疗.

关键词:
不典型的EGFR是什么复合性EGFR是一种复合性EGFR.欧洲农业基金 (EGFR) 第19区域.在NSCLCLC中,我们可以看到NSCLCLC.奥西默蒂尼布 (Osimertinib) 是一种药物.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K